+8, CEP 8
Acute myeloid leukemia (AML), Chronic myelogenous leukemia (CML), Myelodysplastic syndrome (MDS)
Fluorescence in situ Hybridization (FISH)
2.0 mL (min. 1.0 mL) peripheral blood in sodium heparin preferred, EDTA accepted
1.0 mL (min. 0.5 mL) bone marrow in sodium heparin preferred, EDTA accepted
5 mm^3 fresh tissue or 3.0 mL (min. 2.0 mL) FNA in MPLN RPMI media
Whole blood and bone marrow, ship ambient
Fresh tissue or FNA ship in a Styrofoam container with a cool/refrigerated pack (Do not allow cool pack to directly contact sample)
Clotted specimen; Specimen exposed to extreme temperature; Anticoagulant toxic to cells; Insufficient number of cells
Normal cells have two aqua signals. Abnormal cells containing trisomy 8, have a three aqua signal pattern.
Trisomy 8 is relatively specific for myeloid disorders and is rarely observed in lymphoid disease. It is found in 10-15% of patients with acute myeloid leukemia (AML), 15-20% of patients with myelodysplastic syndromes (MDS), as a secondary abnormality in Philadelphia chromosome positive CML, and in other myeloproliferative disorders. Trisomy 8 occurs as the sole chromosome abnormality in about 40% of AML cases, occurs in combination with simple chromosome changes in 35% of cases, and as part of a complex karyotype in 25% of AML patients.